CBER's Quarterly Safety Review Procedures Less Centralized Than CDER's
This article was originally published in The Pink Sheet Daily
Executive Summary
Under FDAAA, both centers are required to publish evaluations of AERS data. CBER’s review effort is more specialized, while CDER’s procedures are more centralized.
You may also be interested in...
FDA List Of Potential Safety Signals Has 3 Pfizer Drugs, Echoes Drug Watch Site
FDA's quarterly report that lists potential signals of serious risks for drugs is similar in design to a program that the agency proposed and then withdrew following industry criticism
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.